Women advised to pair effective contraception with skinny jabs'
Experts warn that the use of medications like Wegovy and Ozempic, popular for weight loss, may inadvertently lead to unexpected pregnancies due to improved fertility in women with obesity. [ more ]
A New Test Predicts Who Will Benefit Most from Weight-Loss Drugs
Genetic test MyPhenome can predict response to weight-loss drug semaglutide with 75% accuracy, categorizing people into four types of weight gain. [ more ]
Treating Cardiovascular Health with Anti-Obesity Medications and Addressing Health Equity - News Center
GLP-1 receptor agonist medications like semaglutide can reduce the risk of cardiovascular disease in patients with obesity but no diabetes.
Weight-independent effects of semaglutide include reducing inflammation and improving vasculature and kidney health, leading to decreased development of cardiovascular events. [ more ]
How Research is Changing the Conversation about Obesity - News Center
Anti-obesity medications are gaining attention but face access challenges like insurance coverage and stigma.
Research led by Feinberg faculty, such as Dr. Robert Kushner, shows promising results for medications like semaglutide in weight loss treatment. [ more ]
Five hundred new jobs coming in Chartres, south of Paris
Danish pharmaceutical giant Novo Nordisk is investing â¬2.1 billion in a French production site to expand the capacity and manufacturing of its anti-obesity drug.
Novo Nordisk's Semaglutide medication, originally meant for diabetes, is also effective against obesity and has massive global potential.
Goldman Sachs predicts that the global market for anti-obesity medication could reach $100 billion by 2030. [ more ]
Weight-Loss Drug Wegovy Slashes Risk of Death in Some People with Heart Disease
Semaglutide, a drug used to treat diabetes and aid weight loss, has been found to lower the risk of heart attack, stroke, and death from cardiovascular disease by 20%
The drug works by regulating appetite hormones and causing people to feel full longer, leading to weight loss and reduced cardiovascular risk
The results of the trial show promise for reducing cardiovascular risk in overweight or obese individuals [ more ]
Weight Loss Drug Wegovy Can Also Reduce Risk of Serious Heart Events, Study Shows
The weight loss drug semaglutide, sold under brand names Wegovy, Ozempic, and Rybelsus, has been found to reduce the risk of dying from heart disease in some patients.
A study involving over 17,000 people without diabetes but with a history of heart issues showed that those who received semaglutide lost about 9% of their body weight and reduced their risk of heart attack, stroke, or death from a heart event by 20%.
The results of the study were presented at the American Heart Association meeting and published in the New England Journal of Medicine. [ more ]